Harnessing MerTK agonism for targeted therapeutics

Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fcγ receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies. Unlike Fcγ receptor-mediated phagocytosis, MerTK-mediated phagocytic clearance is immunologically sil...

Descripción completa

Detalles Bibliográficos
Autores principales: Kedage, Vivekananda, Ellerman, Diego, Chen, Yongmei, Liang, Wei-Ching, Borneo, Joven, Wu, Yan, Yan, Minhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927767/
https://www.ncbi.nlm.nih.gov/pubmed/31852344
http://dx.doi.org/10.1080/19420862.2019.1685832
_version_ 1783482352925671424
author Kedage, Vivekananda
Ellerman, Diego
Chen, Yongmei
Liang, Wei-Ching
Borneo, Joven
Wu, Yan
Yan, Minhong
author_facet Kedage, Vivekananda
Ellerman, Diego
Chen, Yongmei
Liang, Wei-Ching
Borneo, Joven
Wu, Yan
Yan, Minhong
author_sort Kedage, Vivekananda
collection PubMed
description Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fcγ receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies. Unlike Fcγ receptor-mediated phagocytosis, MerTK-mediated phagocytic clearance is immunologically silent. Here, we describe a bispecific antibody approach to harness MerTK for targeted clearance without inducing proinflammatory cytokine release associated with Fcγ receptor engagement. We generated bispecific antibodies targeting live B cells or amyloid beta aggregates to demonstrate the feasibility and versatility of this new approach.
format Online
Article
Text
id pubmed-6927767
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-69277672020-01-03 Harnessing MerTK agonism for targeted therapeutics Kedage, Vivekananda Ellerman, Diego Chen, Yongmei Liang, Wei-Ching Borneo, Joven Wu, Yan Yan, Minhong MAbs Short Communication Phagocytosis plays important roles both in homeostasis and under pathological conditions. Fcγ receptor-mediated phagocytosis has been exploited as an integral mechanism for antibody-based therapies. Unlike Fcγ receptor-mediated phagocytosis, MerTK-mediated phagocytic clearance is immunologically silent. Here, we describe a bispecific antibody approach to harness MerTK for targeted clearance without inducing proinflammatory cytokine release associated with Fcγ receptor engagement. We generated bispecific antibodies targeting live B cells or amyloid beta aggregates to demonstrate the feasibility and versatility of this new approach. Taylor & Francis 2019-12-18 /pmc/articles/PMC6927767/ /pubmed/31852344 http://dx.doi.org/10.1080/19420862.2019.1685832 Text en © 2019 Genentech. Published with license by Taylor & Francis Group, LLC https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Kedage, Vivekananda
Ellerman, Diego
Chen, Yongmei
Liang, Wei-Ching
Borneo, Joven
Wu, Yan
Yan, Minhong
Harnessing MerTK agonism for targeted therapeutics
title Harnessing MerTK agonism for targeted therapeutics
title_full Harnessing MerTK agonism for targeted therapeutics
title_fullStr Harnessing MerTK agonism for targeted therapeutics
title_full_unstemmed Harnessing MerTK agonism for targeted therapeutics
title_short Harnessing MerTK agonism for targeted therapeutics
title_sort harnessing mertk agonism for targeted therapeutics
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927767/
https://www.ncbi.nlm.nih.gov/pubmed/31852344
http://dx.doi.org/10.1080/19420862.2019.1685832
work_keys_str_mv AT kedagevivekananda harnessingmertkagonismfortargetedtherapeutics
AT ellermandiego harnessingmertkagonismfortargetedtherapeutics
AT chenyongmei harnessingmertkagonismfortargetedtherapeutics
AT liangweiching harnessingmertkagonismfortargetedtherapeutics
AT borneojoven harnessingmertkagonismfortargetedtherapeutics
AT wuyan harnessingmertkagonismfortargetedtherapeutics
AT yanminhong harnessingmertkagonismfortargetedtherapeutics

Ejemplares similares